Three Or More Ring Hetero Atoms In The Tricyclo Ring System Patents (Class 546/82)
-
Patent number: 6699878Abstract: Imidazonaphthyridine compounds that are unsubstituted at the 2-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: GrantFiled: October 7, 2002Date of Patent: March 2, 2004Assignee: 3M Innovative Properties CompanyInventors: Kyle J. Lindstrom, Michael J. Rice
-
Patent number: 6696460Abstract: Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.Type: GrantFiled: March 25, 2002Date of Patent: February 24, 2004Assignee: Atlanta Pharma AGInventor: Jörg Senn-Bilfinger
-
Patent number: 6696461Abstract: Compounds of formula (I) in which the substituents as defined in the description are useful for preventing and treating gastrointestinal disorders.Type: GrantFiled: October 4, 2002Date of Patent: February 24, 2004Assignee: Altana Pharma AGInventors: Jörg Senn-Bilfinger, Wilm Buhr, Reinhard Huber, Ernst Sturm
-
Patent number: 6693113Abstract: The imidazonaphthyridine compound, 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine, induces the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compound exhibits antiviral and antitumor properties. Methods of preparing the compound and intermediates useful in the preparation of the compound are also disclosed.Type: GrantFiled: June 27, 2002Date of Patent: February 17, 2004Assignee: 3M Innovative Properties CompanyInventor: Kyle J. Lindstrom
-
Publication number: 20040023932Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: ApplicationFiled: April 3, 2003Publication date: February 5, 2004Applicant: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
-
Publication number: 20040024008Abstract: The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection or autoimmune disease.Type: ApplicationFiled: July 28, 2003Publication date: February 5, 2004Applicant: WyethInventors: Neal Jeffrey Green, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen
-
Patent number: 6686472Abstract: Methods of preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce the biosynthesis of various cytokines including interferon, and they inhibit tumor formation in animal models.Type: GrantFiled: May 13, 2003Date of Patent: February 3, 2004Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
-
Patent number: 6686373Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein the dashed lines represent optional double bonds; C1, C2, C3 and C4 are carbon atom; R1 is C1-4 alkyl; R2 is H, amino, etc.; R3 is H, halo-CH2—, C2-8 alkyl or Q1-, wherein said C2-8 alkyl is optionally substituted with up to 3 substituents selected from halo, C1-3 alkyl, R4(R5)N, etc.; R4 is H, C1-7 alkyl, etc.; R5 is H, C1-7alkyl, etc.; R6 and R7 are independently selected from H and C1-4 alkyl; R8 is aryl or heteroaryl; Q1 is a 4-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4 alkyl, etc.; Y5, Y6, Y7 and Y8 are hydrogen; Y1, Y2, Y3 and Y4 are independently selected from hydrogen, halo, etc.Type: GrantFiled: July 9, 2002Date of Patent: February 3, 2004Assignee: Warner-Lambert Company LLCInventors: Kiyoshi Kawamura, Sachiko Mihara, Seiji Nukui, Chikara Uchida
-
Publication number: 20040019048Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: February 20, 2003Publication date: January 29, 2004Applicant: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Patent number: 6683088Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: January 27, 2004Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
-
Publication number: 20040014754Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: January 28, 2003Publication date: January 22, 2004Applicant: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, Bryon A. Merrill, Michael J. Rice
-
Patent number: 6677349Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: April 28, 2003Date of Patent: January 13, 2004Assignee: 3M Innovative Properties CompanyInventor: George W. Griesgraber
-
Patent number: 6677348Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: January 13, 2004Assignee: 3M Innovative Properties CompanyInventors: Phillip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
-
Patent number: 6677347Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: January 13, 2004Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
-
Publication number: 20040006098Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: ApplicationFiled: April 2, 2003Publication date: January 8, 2004Applicant: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
-
Patent number: 6670373Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.Type: GrantFiled: July 2, 2002Date of Patent: December 30, 2003Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Sreenivasarao Vepachedu, Yongping Xie
-
Patent number: 6670371Abstract: Disclosed are compounds of the formula: wherein Ar is optionally substituted aryl or heteroaryl R1 is hydrogen or alkyl; R7 is hydrogen or alkyl; R2 is hydrogen, halogen, alkyl or alkoxy; or R1 and R2 taken together with the ring to which they are attached form a 5-9 membered saturated or aromatic ring optionally having a hetero atom selected from oxygen, sulfur or nitrogen; R3 and R4 are independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl groups; or R3 and R4 together with the nitrogen atom to which they are attached form a 5-8 membered ring; and R5 is hydrogen, halogen, straight or branched chain lower alkyl having 1-6 carbon atoms, or straight or branched chain lower alkoxy or thioalkoxy having 1-6 carbon atoms, which compounds are highly selective partial agonists or antagonists at human Corticotropin-Releasing Factor 1 (CRF1) receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post trumatic stress disorder (PTSD) as welType: GrantFiled: March 12, 2002Date of Patent: December 30, 2003Assignee: Neurogen CorporationInventors: Raymond F. Horvath, Alan Hutchison
-
Patent number: 6670372Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 30, 2003Assignee: 3M Innovative Properties CompanyInventors: Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
-
Patent number: 6667312Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: December 23, 2003Assignee: 3M Innovative Properties CompanyInventors: Jason D. Bonk, Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
-
Patent number: 6667405Abstract: Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring or a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; p1 represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different.Type: GrantFiled: November 1, 2001Date of Patent: December 23, 2003Assignee: Fuji Photo Film Co., Ltd.Inventors: Katsumi Kobayashi, Takashi Katoh, Junji Nishigaki
-
Publication number: 20030232847Abstract: The present invention discloses compounds corresponding to formula I: 1Type: ApplicationFiled: April 3, 2003Publication date: December 18, 2003Inventors: David Michael Goldstein, Ronald Charles Hawley, Alfred Sui-Ting Lui, Eric Brian Sjogren
-
Patent number: 6664260Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and heterocyclyl or heteroaryl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 16, 2003Assignee: 3M Innovative Properties CompanyInventors: Leslie J. Charles, Joseph F. Dellaria, George W. Griesgraber, Philip D. Heppner, Karl J. Manske, John W. Mickelson, Michael J. Rice
-
Patent number: 6664264Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 16, 2003Assignee: 3M Innovative Properties CompanyInventors: Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
-
Patent number: 6664265Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: December 16, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Byron A. Merrill
-
Patent number: 6660747Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 9, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 6660735Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: December 9, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 6656938Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 2, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Publication number: 20030216429Abstract: The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives of the general formula (I) or (II) 1Type: ApplicationFiled: April 3, 2003Publication date: November 20, 2003Inventors: Zhihua Sui, Mark Macielag, James C. Lanter
-
Publication number: 20030212092Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: June 7, 2002Publication date: November 13, 2003Inventors: Philip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
-
Publication number: 20030212270Abstract: 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.Type: ApplicationFiled: May 13, 2003Publication date: November 13, 2003Applicant: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom
-
Publication number: 20030212091Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 6, 2001Publication date: November 13, 2003Inventors: Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
-
Publication number: 20030212093Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: ApplicationFiled: October 7, 2002Publication date: November 13, 2003Applicant: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
-
Patent number: 6642222Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.Type: GrantFiled: May 3, 2000Date of Patent: November 4, 2003Assignee: Abbott LaboratoriesInventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
-
Patent number: 6642249Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined.Type: GrantFiled: June 26, 2002Date of Patent: November 4, 2003Assignee: Active Biotech ABInventors: Per Axel Björk, Tomas Fex, Lars Olof Göran Pettersson, Pous Sørensen, Dorthe Da Graça Thrige
-
Publication number: 20030203901Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.Type: ApplicationFiled: November 25, 2002Publication date: October 30, 2003Applicant: SUGEN, INC.Inventors: Peng Cho Tang, Li Sun
-
Patent number: 6638944Abstract: Imidazonaphthyridine compounds that have a urea containing substituent at the 1-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: GrantFiled: June 27, 2002Date of Patent: October 28, 2003Assignee: 3M Innovative Properties CompanyInventor: John W. Mickelson
-
Patent number: 6635759Abstract: The invention relates to a substituted 4-trifluoromethyl carbostyril according to formula (I) and is characterised in that the 4-trifluoromethyl carbostyril is provided with an absorption maximum between 350 and 420 nm and a luminescence maximum between 430 and 900 nm. The molecule can be substituted with groups that are useful for complexing metal ions and/or for binding the molecule to relevant groups of a target molecule or a solid supporting material. The carbostyril as described above can inter alia serve as an antenna molecule of a lanthanide complex. Said complexes can be templates and can be brought into contact with a directly bound or free colour molecule which absorbs in the rant of 580-710 nm. Luminescence effects and decay periods can be measured after the contact with a relevant analyte.Type: GrantFiled: December 31, 2001Date of Patent: October 21, 2003Inventors: Georg Uray, Karlheinz Niederreiter
-
Patent number: 6632809Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.Type: GrantFiled: December 12, 2001Date of Patent: October 14, 2003Assignee: Vertex Pharmaceuticals IncorporatedInventors: Anne-Laure Grillot, Paul Charifson, Dean Stamos, Yusheng Liao, Michael Badia, Martin Trudeau
-
Patent number: 6630588Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.Type: GrantFiled: February 19, 2002Date of Patent: October 7, 2003Assignee: 3M Innovative Properties CompanyInventors: Michael J. Rice, Mark A. Tomai, Ai-Ping Wei
-
Publication number: 20030187016Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: June 7, 2002Publication date: October 2, 2003Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Publication number: 20030186082Abstract: This invention features a dipyrazolo-pyridine compound of formula (I): 1Type: ApplicationFiled: November 14, 2002Publication date: October 2, 2003Inventors: Yu-Tai Tao, Chung-Wen Ko, Chang-Hao Chuen, Jing-Wen Peng
-
Patent number: 6627638Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.Type: GrantFiled: September 12, 2002Date of Patent: September 30, 2003Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
-
Publication number: 20030181455Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: January 28, 2003Publication date: September 25, 2003Applicant: Neurogen Corporation, A Corporation of the State of DelawareInventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
-
Patent number: 6624172Abstract: Imidazonaphthydrine compounds that have an aryl containing substituent at the 1-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.Type: GrantFiled: August 31, 2001Date of Patent: September 23, 2003Assignee: 3M Innovative Properties CompanyInventors: Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Patent number: 6624305Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.Type: GrantFiled: February 6, 2003Date of Patent: September 23, 2003Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom
-
Publication number: 20030171394Abstract: Compounds of formula I 1Type: ApplicationFiled: January 22, 2003Publication date: September 11, 2003Inventors: Irene Drizin, Robert J. Altenbach, William A. Carroll
-
Publication number: 20030166929Abstract: Disclosed are novel compounds of formula (I): 1Type: ApplicationFiled: November 12, 2002Publication date: September 4, 2003Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Mario G. Cardozo, Daniel R. Goldberg, Abdelhakim Hammach, Tina M. Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hindenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Patent number: 6613902Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.Type: GrantFiled: January 28, 2003Date of Patent: September 2, 2003Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom
-
Publication number: 20030158193Abstract: Compounds of the formula 1 1Type: ApplicationFiled: September 27, 2002Publication date: August 21, 2003Inventors: J?ouml;rg Senn-Bilfinger, Wilm Buhr
-
Publication number: 20030158192Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 6, 2001Publication date: August 21, 2003Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill